Aster DM Quality Care Ltd
Aster DM Quality Care Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
QCIL expects continued strong growth momentum in both revenue and margins for the next two years, supported by about 900 additional beds being added in this period. Q4 FY26 showed strong growth with revenue up 18% YoY and EBITDA up 23% YoY; full-year EBITDA grew 24.1% YoY, crossing INR 1,000 crores for the first time.
From Aster DM Quality Care Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- QCIL expects continued strong growth momentum in both revenue and margins for the next two years, supported by about 900 additional beds being added in this period.
- Mature hospitals show steady growth (~13.5-14% revenue growth YoY) with EBITDA expansion driven by complexity enhancement and oncology volume growth.
- Emerging and focused units report robust ramp-ups: emerging units grew 62.4% YoY in revenue; focused units grew 21% YoY with improved EBITDA margins.
- Patient volumes are rising with IP volumes up 7-10% yearly and OP footfalls growing similarly, driving revenue increases.
- Expansion plans include adding beds in Raipur, Bhubaneswar, Banjara, Nagercoil (+100 beds), Nampally (+28 beds), Malakpet, Chattogram, Vizag, and Indore (greenfield).
- Continued focus on clinical talent attraction and specialty capability upgrades to enhance case mix and ARPOB (average revenue per occupied bed).
2 more points from Aster DM Quality Care Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Aster DM Quality Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- For FY26, capital expenditure was INR 549 crores, with 45% towards expansion projects.
- Operationalized:
- Whitefield Block D with 159 beds (April 2026).
- Aster Ramesh Sanghamitra Ongole brownfield expansion with 75 beds (April 2026).
- Plans to add ~2,500 beds over the next 4 years at a cost of INR 2,700 crores; INR 350 crores invested till March 2026.
- QCIL expansion budget is around INR 2,000 crores for 1,700 beds (1,500 brownfield, 200 greenfield).
- Per bed capex:
- Brownfield: INR 0.8-1.1 crores.
- Greenfield: INR 1.5-1.6 crores.
- Focus on sprucing up existing assets, adding clinical capabilities, and enhancing oncology services (e.g., Banjara).
2 more points from Aster DM Quality Care Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aster DM Quality Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- QCIL has an expansion budget of around INR 2,000 crores for approximately 1,700 beds.
- Out of these, around 1,500 beds are planned as brownfield projects.
- The blended per bed capex is approximately INR 1-1.1 crores.
- Greenfield per bed capex is higher, around INR 1.5-1.6 crores, while brownfield is in the range of INR 0.8-1.1 crores.
- For Aster DM Healthcare, over the next four years, there is a plan to add about 2,500 beds at a cost of INR 2,700 crores.
2 more points from Aster DM Quality Care Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Aster DM Quality Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.2K Cr, net profit ₹154 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aster DM Quality Care Ltd's management said in earlier quarters
- Q1 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Healthcare Services this season
- Suven Life Scie. (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su
- Invicta Diagnos. (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnos.'s Q4 FY26 earnings…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
- Gaudium IVF and Women Health Ltd (Q4 FY26)
Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25. Key concall takeaways from Gaudium IVF's Q4 FY26 earnings call — and how it ranks…
Arthneeti Pro · Annual
Aster DM Quality Care Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aster DM Quality Care Ltd Q4 FY26 results?
QCIL expects continued strong growth momentum in both revenue and margins for the next two years, supported by about 900 additional beds being added in this period. Q4 FY26 showed strong growth with revenue up 18% YoY and EBITDA up 23% YoY; full-year EBITDA grew 24.1% YoY, crossing INR 1,000 crores for the first time.
What is Aster DM Quality Care Ltd share price analysis?
Aster DM Quality Care Ltd currently shows a neutral. The stock trades at a P/E of 203.4 with a market cap of ₹73,404 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aster DM Quality Care Ltd planning capital expenditure?
For FY26, capital expenditure was INR 549 crores, with 45% towards expansion projects.
Keep Aster DM Quality Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
